Apricus Biosciences Receives Nasdaq Compliance Notice

Apricus Biosciences Receives Nasdaq Compliance Notice

Apricus Biosciences, Inc. , a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that on November 30, 2016, the Company received notice from the Nasdaq Listing Qualifications Staff that due to the Company's non-compliance with the $35 million market value of listed securities requirement, the Company was subject to delisting unless it timely requests a hearing before the Nasdaq Hearings Panel . The Company intends to timely request a hearing before the Panel, which request will stay any delisting action by the Staff, pending the Panel's decision.

from Biotech News